Karine Pérès

Karine Pérès

Auto-generated profile, based on publicly available information

Karine Pérès

Univ. Bordeaux, INSERM UMR 1219, Bordeaux Population Health Research Center, Bordeaux, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2017 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
YWYu-Tzu Wu
Yu-Tzu Wu
ABAlexa S. Beiser
Alexa S. Beiser
MBMonique M. B. Breteler
Monique M. B. Breteler
LFLaura Fratiglioni
Laura Fratiglioni
CHCatherine Helmer
Catherine Helmer
CBCarol Brayne
Carol Brayne

1 November 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
HAHélène Amieva
Hélène Amieva
MGMélanie Le Goff
Mélanie Le Goff
XMXavier Millet
Xavier Millet
JOJean Marc Orgogozo
Jean Marc Orgogozo
KPKarine Pérès
Karine Pérès
JDJean François Dartigues
Jean François Dartigues

18 March 2015 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KJKatrin Jekel
Katrin Jekel
MDMarinella Damian
Marinella Damian
CWCarina Wattmo
Carina Wattmo
LHLucrezia Hausner
Lucrezia Hausner
RBRoger Bullock
Roger Bullock
LFLutz FROELICH
Lutz FROELICH
Introduction: There is a growing body of evidence that subtle deficits in instrumental activities of daily living (IADL) may be present in mild cognitive impairment (MCI). However, it is not clear if there are IADL domains that are consistently affected across patients with MCI. In this systematic review, therefore, we aimed to summarize research results regarding the performance of MCI patients in specific IADL (sub)domains compared with persons who are cognitively normal and/or patients with dementia. Methods: The databases PsycINFO, PubMed and Web of Science were searched for relevant literature in December 2013. Publications from 1999 onward were considered for inclusion. Altogether, 497 articles were retrieved. Reference lists of selected articles were searched for potentially relevant articles. After screening the abstracts of these 497 articles, 37 articles were included in this review. Results: In 35 studies, IADL deficits (such as problems with medication intake, telephone use, keeping appointments, finding things at home and using everyday technology) were documented in patients with MCI. Financial capacity in patients with MCI was affected in the majority of studies. Effect sizes for group differences between patients with MCI and healthy controls were predominantly moderate to large. Performance-based instruments showed slight advantages (in terms of effect sizes) in detecting group differences in IADL functioning between patients with MCI, patients with Alzheimer’s disease and healthy controls. Conclusion: IADL requiring higher neuropsychological functioning seem to be most severely affected in patients with MCI. A reliable identification of such deficits is necessary, as patients with MCI with IADL deficits seem to have a higher risk of converting to dementia than patients with MCI without IADL deficits. The use of assessment tools specifically designed and validated for patients with MCI is therefore strongly recommended. Furthermore, the development of performance-based assessment instruments should be intensified, as they allow a valid and reliable assessment of subtle IADL deficits in MCI, even if a proxy is not available. Another important point to consider when designing new scales is the inclusion of technology-associated IADL. Novel instruments for clinical practice should be time-efficient and easy to administer.

26 October 2002 in BMJ
Verified
Journal Article
Closed access
PDF file
PBPascale Barberger-Gateau
Pascale Barberger-Gateau
LLLuc Letenneur
Luc Letenneur
VDValérie Deschamps
Valérie Deschamps
KPKarine Pérès
Karine Pérès
JDJean-François Dartigues
Jean-François Dartigues
SRSerge Renaud
Serge Renaud
We calculated the incidence of dementia per 100 person years. We used a Cox proportional hazards model with delayed entry to estimate the relative risk of dementia, taking into account age, sex, and education (at least the French primary school diploma “Certificat d'Etudes Primaires” versus less education3).

27 September 2012 in BMJ
Verified
Journal Article
Open access
PDF file
SGSophie Billioti de Gage
Sophie Billioti de Gage
BBBernard Bégaud
Bernard Bégaud
FBFabienne Bazin
Fabienne Bazin
HVHélène Verdoux
Hélène Verdoux
JDJean-François Dartigues
Jean-François Dartigues
APAntoine Pariente
Antoine Pariente
Objective To evaluate the association between use of benzodiazepines and incident dementia. Design Prospective, population based study. Setting PAQUID study, France. Participants 1063 men and women (mean age 78.2 years) who were free of dementia and did not start taking benzodiazepines until at least the third year of follow-up. Main outcome measures Incident dementia, confirmed by a neurologist. Results During a 15 year follow-up, 253 incident cases of dementia were confirmed. New use of benzodiazepines was associated with an increased risk of dementia (multivariable adjusted hazard ratio 1.60, 95% confidence interval 1.08 to 2.38). Sensitivity analysis considering the existence of depressive symptoms showed a similar association (hazard ratio 1.62, 1.08 to 2.43). A secondary analysis pooled cohorts of participants who started benzodiazepines during follow-up and evaluated the association with incident dementia. The pooled hazard ratio across the five cohorts of new benzodiazepine users was 1.46 (1.10 to 1.94). Results of a complementary nested case-control study showed that ever use of benzodiazepines was associated with an approximately 50% increase in the risk of dementia (adjusted odds ratio 1.55, 1.24 to 1.95) compared with never users. The results were similar in past users (odds ratio 1.56, 1.23 to 1.98) and recent users (1.48, 0.83 to 2.63) but reached significance only for past users. Conclusions In this prospective population based study, new use of benzodiazepines was associated with increased risk of dementia. The result was robust in pooled analyses across cohorts of new users of benzodiazepines throughout the study and in a complementary case-control study. Considering the extent to which benzodiazepines are prescribed and the number of potential adverse effects of this drug class in the general population, indiscriminate widespread use should be cautioned against.

20 November 2007 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
KPKarine Pérès
Karine Pérès
CHCatherine Helmer
Catherine Helmer
HAHélène Amieva
Hélène Amieva
JOJean‐Marc Orgogozo
Jean‐Marc Orgogozo
IRIsabelle Rouch
Isabelle Rouch
PBPascale Barberger‐Gateau
Pascale Barberger‐Gateau